Teladoc’s second quarter results were met with a significant negative market reaction, as revenue declined year-over-year and missed Wall Street expectations. Management attributed the underperformance primarily to accelerated declines in its BetterHelp cash pay business, driven by a faster-than-anticipated consumer shift toward insurance and capacity constraints in its provider network. CEO Charles Divita acknowledged, “the increasing speed of consumer movement towards insurance provider capacity and network constraints against this increased demand... became more pronounced and persistent than the assumptions underlying our prior outlook.” The company’s integrated care segment, however, saw moderate revenue growth, supported by chronic care enrollment and international demand.
Is now the time to buy TDOC? Find out in our full research report (it’s free for active Edge members).
Teladoc (TDOC) Q2 CY2026 Highlights:
- Revenue: $606.9 million vs analyst estimates of $615 million (4% year-on-year decline, 1.3% miss)
- EPS (GAAP): -$0.21 vs analyst estimates of -$0.25 (15.5% beat)
- Adjusted EBITDA: $65.71 million vs analyst estimates of $62.25 million (10.8% margin, 5.6% beat)
- The company dropped its revenue guidance for the full year to $2.40 billion at the midpoint from $2.53 billion, a 4.9% decrease
- EPS (GAAP) guidance for the full year is -$0.88 at the midpoint, beating analyst estimates by 4.2%
- EBITDA guidance for the full year is $287 million at the midpoint, above analyst estimates of $279.8 million
- Operating Margin: -6.1%, up from -8.6% in the same quarter last year
- Market Capitalization: $1.22 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Teladoc’s Q2 Earnings Call
- Sarah James (Cantor Fitzgerald): Asked about the supply gap for insurance-taking therapists and the timeline to close it; CEO Charles Divita emphasized recruitment, delegated credentialing, and onboarding initiatives, but declined to specify timing, stating, “we have got number of things underway.”
- Lisa Gill (JPMorgan Chase & Co.): Inquired about insurance reimbursement rates and margin implications for therapists transitioning from cash pay; Divita explained that insurance requires more administrative effort and brings lower gross margins but offers potentially higher lifetime value and operating leverage as the business scales.
- George Hill (Deutsche Bank): Sought clarity on whether capacity shortfalls are due to licensing or compensation issues; Divita noted both factors play a role and highlighted recruitment efforts both within and outside the existing therapist network to address demand.
- Daniel Grosslight (Citigroup): Questioned the decision to deprioritize international BetterHelp markets and asked when investment might resume; Divita described the shift as a near-term resource prioritization for U.S. insurance scaling, with long-term international opportunities intact.
- Jailendra Singh (Truist Securities): Asked about integrated care sales trends and Teladoc 1’s impact; Divita reported that selling season was in line with expectations, with client interest in integrated and bundled solutions, and early positive feedback on Teladoc 1.
Catalysts in Upcoming Quarters
Looking ahead, our analysts will closely track (1) progress in expanding therapist network capacity and improving insurance user conversion, (2) the impact of reduced advertising spend on cash pay trends and overall BetterHelp profitability, and (3) adoption of Teladoc 1 and chronic care bundles in integrated care. Developments in international strategy and the scale of insurance-driven growth will also be key indicators of execution.
Teladoc currently trades at $6.73, down from $9.18 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
